| PATENT NUMBER | This data is not available for free |
| PATENT GRANT DATE | 31.12.02 |
| PATENT TITLE |
Human thyroid protein ZSIG45 |
| PATENT ABSTRACT | The present invention relates to polynucleotide and polypeptide molecules for zsig45, a novel human protein expressed in thyroid. The polypeptides, and polynucleotides encoding them, may be used for detecting human disease states and chromosomal abnormalities, and as a therapeutic. The present invention also includes antibodies to the zsig45 polypeptides |
| PATENT INVENTORS | This data is not available for free |
| PATENT ASSIGNEE | This data is not available for free |
| PATENT FILE DATE | March 10, 2000 |
| PATENT REFERENCES CITED |
Rudinger, J. "Characteristics of the amino acids as components of a peptide hormone sequence.", in Peptide Hormones, Parsons, J.A. ed., University Park Press, Baltimore, MD, p. 6-7, 1976.* Ngo et al. in the Protein Folding Problem and Tertiary Structure Prediction, Merz et al., ed., Birkhauser, Boston, MA, pp. 492-495, 1994.* Bowie et al. Science 247: 1306-1310, 1990.* Strausberg, EMBL Database, Accession No. g374416, 1998. EMBL Database, Accession No. Z99570, 1997. Eggo et al., Mol. Cell. Endocrinol., 100:97-102, 1994. Life SEQ.TM. Clone Information Results, Incyte Pharmaceuticals, Inc., 1996. Life SEQ.TM. Library Information Results, Incyte Pharmaceuticals, Inc., 1997. Life SEQ.TM. Library Information Results, Incyte Pharmaceuticals, Inc., 1996. Life SEQ.TM. Library Information Results, Incyte Pharmaceuticals, Inc., 1997. |
| PATENT PARENT CASE TEXT | This data is not available for free |
| PATENT CLAIMS |
What is claimed is: 1. An isolated polypeptide comprising a sequence of amino acid residues selected from the group consisting of: (a) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 47 (Lys) to amino acid number 114 (Asp) of SEQ ID NO:2; (b) the amino acid sequence as shown in SEQ ID NO:4 from amino acid number 1 (Met) to amino acid number 85 (Asp); (c) the amino acid sequence as shown in SEQ ID NO:3 from amino acid number 1 (Met) to amino acid number 89 (Asp); and (d) the amino acid sequence as shown in SEQ ID NO:2 from amino acid residue number 1 (Met) to amino acid residue number 114 (Asp). 2. An isolated polypeptide according to claim 1, wherein the sequence of amino acid residues comprises SEQ ID NO:2 from amino acid number 47 (Lys) to amino acid number 114 (Asp). 3. An isolated polypeptide according to claim 1, wherein the isolated polypeptide further binds an antibody to the isolated polypeptide, and wherein the antibody is raised to a polypeptide comprising a sequence of amino acids from the group consisting of: (a) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 47 (Lys) to amino acid number 114 (Asp) of SEQ ID NO:2; (b) the amino acid sequence as shown in SEQ ID NO:4 from amino acid number 1 (Met) to amino acid number 85 (Asp); (c) the amino acid sequence as shown in SEQ ID NO:3 from amino acid number 1 (Met) to amino acid number 89 (Asp); and (d) the amino acid sequence as shown in SEQ ID NO:2 from amino acid residue number 1 (Met) to amino acid residue number 114 (Asp); and wherein the binding of the antibody to the isolated polypeptide is measured by a biological or biochemical assay such as a radioimmunoassay, radioimmuno-precipitation, Western blot, or enzyme-linked immunosorbent assay. 4. An isolated polypeptide according to claim 1, wherein the polypeptide has proinflammatory activity. 5. An isolated polypeptide of claim 1 further comprising an affinity tag, radionuclide, enzyme, substrate, cofactor, inhibitor, fluorescent marker, chemiluminescent marker, or magnetic particle. 6. An isolated polypeptide of claim 2 further comprising an affinity tag, radionuclide, enzyme, substrate, cofactor, inhibitor, fluorescent marker, chemiluminescent marker, or magnetic particle. 7. An isolated fusion polypeptide comprising: a first segment comprising a polypeptide having a sequence of amino acids selected from the group consisting of: (a) amino acids 1 through 46 of SEQ ID NO:2; (b) amino acids 1 through 21 of SEQ ID NO:3; (c) amino acids 1 through 17 of SEQ ID NO:4; and (d) amino acids 47 through 114 of SEQ ID NO:2; and a second segment comprising an additional polypeptide, wherein the first and second segments are connected; and comprise the fusion protein. 8. An isolated polypeptide consisting of a sequence of amino acid residues selected from the group consisting of: (a) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 47 (Lys) to amino acid number 114 (Asp) of SEQ ID NO:2; (b) the amino acid sequence as shown in SEQ ID NO:4 from amino acid number 1 (Met) to amino acid number 85 (Asp); (c) the amino acid sequence as shown in SEQ ID NO:3 from amino acid number 1 (Met) to amino acid number 89 (Asp); and (d) the amino acid sequence as shown in SEQ ID NO:2 from amino acid residue number 1 (Met) to amino acid residue number 114 (Asp). 9. An isolated polypeptide according to claim 8, wherein the sequence of amino acid residues consists of SEQ ID NO:2 from amino acid number 47 (Lys) to amino acid number 114 (Asp). 10. An isolated polypeptide according to claim 8, wherein the isolated polypeptide further binds an antibody to the isolated polypeptide, and wherein the antibody is raised to a polypeptide comprising a sequence of amino acids from the group consisting of: (a) the amino acid sequence as shown in SEQ ID NO:2 from amino acid number 47 (Lys) to amino acid number 114 (Asp) of SEQ ID NO:2; (b) the amino acid sequence as shown in SEQ ID NO:4 from amino acid number 1 (Met) to amino acid number 85 (Asp); (c) the amino acid sequence as shown in SEQ ID NO:3 from amino acid number 1 (Met) to amino acid number 89 (Asp); and (d) the amino acid sequence as shown in SEQ ID NO:2 from amino acid residue number 1 (Met) to amino acid residue number 114 (Asp); and wherein the binding of the antibody to the isolated polypeptide is measured by a biological or biochemical assay such as a radioimmunoassay, radioimmuno-precipitation, Western blot, or enzyme-linked immunosorbent assay. 11. An isolated polypeptide according to claim 8, wherein the polypeptide has proinflammatory activity. 12. An isolated polypeptide of claim 8 further comprising an affinity tag, radionuclide, enzyme, substrate, cofactor, inhibitor, fluorescent marker, chemiluminescent marker, or magnetic particle. -------------------------------------------------------------------------------- |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |